Morris & Dickson partners with Mark Cuban Cost Plus DrugsThe partnership aims to mitigate drug shortages, democratize access, enhance flexibility and streamline procurement. AAM comments on Section 232 investigation on pharmaceuticalsAAM said tariffs will exacerbate drug shortages that hinder patient access today. FDA grants interchangeable designation for Celltrion’s Yuflyma Yuflyma is a high-concentration and citrate-free formulation of Humira biosimilar, approved for multiple inflammatory indications. Biocon Biologics secures market entry date for Eylea biosimilar Yesafili, a vascular endothelial growth factor inhibitor, is used to treat several different types of ophthalmology conditions and is a biosimilar of its Eylea. Nexus Pharmaceuticals debuts baclofen injection refill kit This kit is intended to ease the lives of those living with long-term severe spasticity conditions. Camber launches lurasidone hydrochloride tablets Lurasidone hydrochloride tablets are an atypical antipsychotic. AAM commends Senate Q1/Q2 bill introduction The legislation would save more than $800 million over 10 years and brings lower-cost medicines to patients sooner, AAM said. Strides Pharma’s subsidiary incorporates Pivot Path Pivot Path will focus on life sciences and manufacturing solutions, using its cutting-edge technology capabilities. Aurobindo Pharma receives FDA OK for generic Xarelto Generic Xarelto is a blood thinner medicine that lowers blood clotting. Sandoz files antitrust litigation against Amgen regarding entanercept biosimilar Sandoz is seeking damages in addition to clearing a path for launch. 1 2 3 4 5 Next Last
